{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:51Z","timestamp":1793148351939,"version":"4.5.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"\n Importance<\/jats:title>\n Autoimmune disorders can affect various organs and if refractory, can be life threatening. Recently, CD19-targeting\u2013chimeric antigen receptor (CAR) T cells were efficacious as an immune suppressive agent in 6 patients with refractory systemic lupus erythematosus and in 1 patient with antisynthetase syndrome.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To test the safety and efficacy of CD19-targeting CAR T cells in a patient with severe antisynthetase syndrome, a complex autoimmune disorder with evidence for B- and T-cell involvement.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This case report describes a patient with antisynthetase syndrome with progressive myositis and interstitial lung disease refractory to available therapies (including rituximab and azathioprine), who was treated with CD19-targeting CAR T cells in June 2022 at University Hospital T\u00fcbingen in T\u00fcbingen, Germany, with the last follow-up in February 2023. Mycophenolate mofetil was added to the treatment to cotarget CD8\n +<\/jats:sup>\n T cells, hypothesized to contribute to disease activity.\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n \n Prior to treatment with CD19-targeting CAR T cells, the patient received conditioning therapy with fludarabine (25 mg\/m\n 2<\/jats:sup>\n [5 days before until 3 days before]) and cyclophosphamide (1000 mg\/m\n 2<\/jats:sup>\n [3 days before]) followed by infusion of CAR T cells (1.23\u00d710\n 6<\/jats:sup>\n \/kg [manufactured by transduction of autologous T cells with a CD19 lentiviral vector and amplification in the CliniMACS Prodigy system]) and mycophenolate mofetil (2 g\/d) 35 days after CD19-targeting CAR T-cell infusion.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The patient\u2019s response to therapy was followed by magnetic resonance imaging of the thigh muscle, Physician Global Assessment, functional muscle and pulmonary tests, and peripheral blood quantification of anti-Jo-1 antibody levels, lymphocyte subsets, immunoglobulins, and serological muscle enzymes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Rapid clinical improvement was observed after CD19-targeting CAR T-cell infusion. Eight months after treatment, the patient\u2019s scores on the Physician Global Assessment and muscle and pulmonary function tests improved, and there were no detectable signs of myositis on magnetic resonance imaging. Serological muscle enzymes (alanine aminotransferase, aspartate aminotransferase, creatinine kinase, and lactate dehydrogenase), CD8\n +<\/jats:sup>\n T-cell subsets, and inflammatory cytokine secretion in the peripheral blood mononuclear cells (interferon gamma, interleukin 1 [IL-1], IL-6, and IL-13) were all normalized. Further, there was a reduction in anti-Jo-1 antibody levels and a partial recovery of IgA (to 67% of normal value), IgG (to 87%), and IgM (to 58%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n CD19-targeting CAR T cells directed against B cells and plasmablasts deeply reset B-cell immunity. Together with mycophenolate mofetil, CD19-targeting CAR T cells may break pathologic B-cell, as well as T-cell responses, inducing remission in refractory antisynthetase syndrome.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.8753","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T11:33:57Z","timestamp":1687865637000},"page":"2154","source":"Crossref","is-referenced-by-count":254,"title":["CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome"],"prefix":"10.1001","volume":"329","author":[{"given":"Ann-Christin","family":"Pecher","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Hensen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Schairer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lutz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Children\u2019s Hospital, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Children\u2019s Hospital, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stanger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Horger","sequence":"additional","affiliation":[{"name":"Department for Diagnostic and Interventional Radiology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Bornemann","sequence":"additional","affiliation":[{"name":"Department of Pathology and Neuropathology and Comprehensive Cancer Center, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Henes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jpc230003r1","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"jpc230003r2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus.","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10379","key":"jpc230003r3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome.","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"jpc230003r4","first-page":"28","article-title":"Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.","volume":"36","author":"Glaeser","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"jpc230003r5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12876-018-0787-x","article-title":"Sulphite oxidase (SO)\u2014a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis.","volume":"18","author":"Preu\u00df","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"20","key":"jpc230003r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cells11203330","article-title":"High-Dimensional cytometry dissects immunological fingerprints of idiopathic inflammatory myopathies.","volume":"11","author":"Nelke","year":"2022","journal-title":"Cells"},{"issue":"Pt 9","key":"jpc230003r7","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody\u2013positive patients show a characteristic necrotizing perifascicular myositis.","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"issue":"4","key":"jpc230003r8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1615\/CritRevImmunol.v38.i4","article-title":"Immunopathogenesis of the anti-synthetase syndrome.","volume":"38","author":"Gayed","year":"2018","journal-title":"Crit Rev Immunol"},{"key":"jpc230003r9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis.","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"jpc230003r10","first-page":"194","article-title":"Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies.","volume":"59","author":"Wilkinson","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"jpc230003r11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804034","article-title":"Single-cell transcriptomics reveals peripheral immune responses in anti-synthetase syndrome-associated interstitial lung disease.","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"jpc230003r12","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1038\/s41467-021-23212-x","article-title":"CD8+ T-cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.","volume":"12","author":"Hensen","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"jpc230003r13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12511","article-title":"Update on the pharmacological treatment of adult myositis.","volume":"280","author":"Oddis","year":"2016","journal-title":"J Intern Med"},{"issue":"5","key":"jpc230003r14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"jpc230003r15","first-page":"352","article-title":"A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.","volume":"26","author":"Adams","year":"1999","journal-title":"J Rheumatol"},{"issue":"4","key":"jpc230003r16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-021-00741-9","article-title":"Regulation of activated T-cell survival in rheumatic autoimmune diseases.","volume":"18","author":"Rosetti","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9388","key":"jpc230003r17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis.","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"jpc230003r18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties.","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2806530\/jama_pecher_2023_pc_230003_1687798706.4558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T11:34:04Z","timestamp":1687865644000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2806530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":18,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.8753","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}